Asuragen Forms Collaborations to Develop FNA Version of Pancreatic Cancer miRNA Test | GenomeWeb

By Doug Macron

Asuragen said this week that it has established a number of collaborations to develop a new version of its microRNA-based pancreatic diagnostic that will use fine-needle aspirate biopsies, rather than samples obtained from formalin-fixed, paraffin-embedded tissues.

The test is expected to be available in the second half of this year through Asuragen's Clinical Laboratory Improvement Amendments-certified lab.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.